Taiwan Resonant Waves Research Corp.

About Us

Taiwan Resonant Waves Research Corp.(TRWR) was founded in 2010 in the capital of Taiwan – Taipei. Integrating innovative bioelectronic technology with medical devices, we are dedicated to helping patients with chronic diseases better manage health-related challenges.

There is unlimited promise in the application of bioelectronic medicine in the treatment of chronic diseases. Designed and developed by TRWR, Microcurrent Electrical Nerve Stimulation technology (MENS) is currently being used as a non-invasive, physical approach to treating and alleviating symptoms associated with diabetes mellitus. Our vision is to lead the world in groundbreaking research and development in electroceutical technology as a means of enhancing quality of life, without the adverse side effects of conventional approaches.

Good news! Taiwan Resonant Waves Research Corp. (TRWR) has acquired Australia, EU, Canada and Russia patents for a diabetes glucagon mitigation system.

Our company has successively acquired patents for a diabetes glucagon mitigation system in Australia, EU, Canada, Russia and South Korea. We are also applying for patents in other countries around the globe.

Our clinical trial began in 2017 and approved by Taiwan Food and Drug Administration (TFDA), has now reached 154 patients.

Our randomized, double-blind trial is underway at National Taiwan University Hospital, National Cheng Kung University Hospital, and two other medical facilities. Under the investigative leadership of 20 medical professionals, the study is expected to be completed in 2020 and potentially become the world’s first non-invasive electronic medical device used to alleviate symptoms associated with type 2 diabetes.

Congrats! TRWR won first place for Innovation at the 2018 RESI (Redefining Early Stage Investments) Conference in Boston.

Experimental Testing, Case Studies, Clinical Trials

Research

Research and development of new indications for Microcurrent Electrical Nerve Stimulation technology (MENS) is based on our proprietary, a non-invasive MENS device. By delivering a patented electric stimulation we developed, it tunes to a specific frequencies combination to improve disease management.

Initial MENS technology adjustments were conducted using animal or cell models for optimization and safety verification, followed by repeated testing of the efficacy of the frequencies combination through subsequent case studies and clinical trials. Results from these studies can serve as a basis for future development of a new indication of MENS technology.

About Us

News

Good news! Taiwan Resonant Waves Research Corp. (TRWR) has acquired Australia, EU, Canada and Russia patents for a diabetes glucagon mitigation system.

Our clinical trial began in 2017 and approved by Taiwan Food and Drug Administration (TFDA), has now reached 154 patients.

Congrats! TRWR won first place for Innovation at the 2018 RESI (Redefining Early Stage Investments) Conference in Boston.

Research

Research

Patent

Clinical Trials

Contact us

+886-2-2521-6333

chrischen082@trwr.com.tw

Social Network